The plasma from PAD patients with adverse events activated AHR activity in ECs 60% more compared with the group without adverse events (P = 0.017) and suppressed Wnt activity in ECs to a greater extent compared with plasma derived from PAD patients without adverse limb events (P = 0.032). The gene discussed is AHR; the disease is peripheral arterial disease.